Latest News

The FDA approved the topical gel with the brand name Ameluz for use with photodynamic therapy for basal cell carcinoma; it is already approved for actinic keratosis.

SERENA-4 missed its PFS end point for camizestrant plus palbociclib vs anastrozole plus palbociclib in untreated advanced breast cancer.

The FDA has approved Pixclara (floretyrosine F 18), the first FET-PET imaging agent for distinguishing recurrent glioma from treatment-related change.

The B7-H3–directed antibody-drug conjugate risvutatug rezetecan improved overall survival in the China-based ARTEMIS-008 study of relapsed extensive-stage small cell lung cancer presented at WCLC.

The FDA approved a label update cutting postinfusion monitoring for the first 2 tarlatamab doses from up to 24 hours down to 6 to 8 hours.

ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

A new NCCN survey found all responding cancer centers report at least one anti-cancer drug shortage, with 94% short on ifosfamide and 71% on carboplatin.

Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.

NHIS analysis reveals major screening gaps for disabled adults—especially self-care limits—while at-home stool tests boost colorectal screening access.

During a live event, Seth M. Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice between systemic therapies for recurrent diffuse tenosynovial giant cell tumor.

The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.

The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

The phase 2 RESTORE-PV trial is exploring the monoclonal antibody DISC-3405 in polycythemia vera across 2 dosing cohorts.

INBRX-106 plus pembrolizumab boosts response rates in first-line PD-L1–positive head and neck cancer, with striking benefits in HPV-positive patients and manageable side effects.

In the SURF302 trial, favorable response rates were seen in the single- and multiple-marker-lesion population, justifying further investigation in the adjuvant bladder cancer setting.

Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just last resort.

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

Mipletamig plus venetoclax and azacitidine delivers 93% clinical benefit in TP53-mutated frontline AML, fueling hopes for a new option.

Scaling back thyroid ultrasonography referrals may meaningfully reduce diagnoses without affecting survival.

The FDA granted accelerated approval to sevabertinib for HER2-mutant, nonsquamous NSCLC regardless of prior systemic therapy, based on SOHO-01 trial data.

In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how anemia and thrombocytopenia in extensive-stage small cell lung cancer are still managed one lineage, and one crisis, at a time.

Geoffrey Y. Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers.

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

DeLLphi-305 data show tarlatamab plus durvalumab significantly improved overall survival as first-line maintenance in extensive stage small cell lung cancer.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

U.S. alcohol-linked cancer deaths double since 1990, led by surging liver cancer; men, older adults hit hardest, with wide state-by-state gaps.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T move earlier.